More aggressive secondary prevention of cardiovascular disease now funded

+Educate
In print
Cardiovascular health

More aggressive secondary prevention of cardiovascular disease now funded

By Chris Ellis
Heart Illustration
[Image: iStock.com – Rasi Bhadramani]

Consultant cardiologist Chris Ellis discusses the recent funding of rosuvastatin, focusing on its use for secondary prevention of cardiovascular disease

Key points, Rosuvastatin 40mg will lower the LDL cholesterol level by approximately 63 per cent, compared with about 55 per cent with atorvastatin 80mg. Ezetimi, Education Blue W/ Grey Background W/ Padding
References

Mach F, Baigent C, Catapano AL, et al. 2019 ESC/EAS Guidelines for the management of dyslipidaemias: lipid modification to reduce cardiovascular risk. Eur Heart J 2020;41(1):11188.